The Effect of Rapid Transcranial Magnetic Stimulation (rTMS) on Aggression in Forensic Patients

Overview

Forensic patients will undergo 30 rTMS treatments, once per day each business day using a 1Hz frequency at the right dorso-lateral pre frontal cortex, located using modified BEAM F3. Patients will be assessed before and after the study with a battery of assessments and using 2 computer tasks: a ball passing task, and the Point Subtraction Aggression Paradigm (PSAP). The investigators will also monitor and record aggressive incidents that take place on the unit.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2020

Interventions

  • Device: rTMS
    • repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)

Arms, Groups and Cohorts

  • Experimental: rTMS
    • treatment with repetitive transcranial magnetic stimulation for 30 days

Clinical Trial Outcome Measures

Primary Measures

  • Change in Aggressive Incident Scale (AIS)
    • Time Frame: 30 days
    • ranking scale of aggressive incidents

Participating in This Clinical Trial

Inclusion Criteria

1. are voluntary and competent to consent to treatment 2. are a current Forensics inpatient at St. Joseph's West 5th Campus 3. demonstrate aggressive behavior as confirmed by a psychologist or psychiatrist including verbal and physical aggression 4. are between the ages of 18 and 65 5. have had no changes in dose or initiation of any psychotropic medication in the 4 weeks prior to motor threshold 6. are willing and able to adhere to the treatment schedule 7. pass the TMS adult Safety-Screening (TASS) Questionnaire Exclusion Criteria:

1. Withdraw consent to participate in the study 2. fail the TASS Safety Screening Questionnaire 3. have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump, or a significant history of seizures 4. have active suicidal intent 5. are pregnant as confirmed by pregnancy test completed as part of pre-study screening 6. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any significant history of seizure except those therapeutically induced by electroconvulsive therapy (ECT), cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis 7. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed 8. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent) due to seizure risk or any dose of an anticonvulsant due to the potential to limit rTMS efficacy 9. non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • St. Joseph’s Healthcare Hamilton
  • Collaborator
    • University Health Network, Toronto
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gary Chaimowitz, Head of Forensics – St. Joseph’s Healthcare Hamilton
  • Overall Official(s)
    • Gary Chaimowitz, MD, FRCPC, Principal Investigator, Head of Forensics
  • Overall Contact(s)
    • Sheila Verhage-Brown, MD, 905-522-1155, sverhage@stjoes.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.